Packaging Improves Compliance - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Packaging Improves Compliance
A decade of awards shows there's no lack of good ideas for compliance packaging.


Pharmaceutical Technology



Hallie Forcinio
Although patient compliance problems have been receiving attention for at least a decade, many medications are still dispensed in bottles that contain a supply intended to last days or weeks and require considerable effort on the part of the patient or caregiver to keep track of the dosing schedule. As a result, when it comes to consistently taking the right dose at the right time for the duration of a prescription, many consumers don't do a very good job.

The failures add up to millions of dollars in unnecessary healthcare costs and lost work time, as well as nursing home admissions and patient illnesses and death. Packaging designed to help patients follow proper dosage regimens could reduce or even eliminate many noncompliance problems.

Compliance packaging is especially important for regimens that require frequent doses, multiple medications, or titrated doses. But it also can help patients remember simple regimens such as once-a-week doses.

For pharmaceutical manufacturers looking for new ideas in compliance packaging, a review of 10 years of winners of the Compliance Package of the Year competition sponsored by the Healthcare Compliance Packaging Council (HCPC, Falls Church, VA, http://www.unitdose.org) is instructive. The winning concepts often are based on blister cards, generally in combination with plastic compacts or paperboard cartons or sleeves, but they also may take other forms.

One example of a nonblister format is the "Medistick" from Merck & Co. (Whitehouse Station, NJ, http://www.merck.com), which won the first Compliance Package of the Year Award competition in 1995. It consists of a narrow, rectangular container with cavities to hold individual doses. Cavities are sealed with printed, peelable film or foil-laminate lidstock. The lidstock is printed with the days and/or times when doses should be taken. To access the medication, the patient or caregiver simply peels away the appropriate section of the lidstock. An injection-molded, flanged cover makes the container child-resistant and protects the lidstock if the package is carried in a pocket or purse. The number of tablets per stick and the number of sticks per package may vary according to the dosage regimen. Sticks generally are injection molded from low-density polyethylene, but any thermoplastic resin may be used. In addition, wall thickness can be increased to reinforce the barrier without resorting to complex multilayer structures. Filling occurs on automated equipment that drops a tablet or capsule, on edge, into each cavity. A jogging seal jaw then seals the lidstock in place.

The 2002 Compliance Package of the Year also won a Medical Design Excellence Award in 2002. The design was based on prefilled syringes. The "SimpleJect Auto-Injector System," developed by Amgen Inc. (Thousand Oaks, CA, http://www.amgen.com) and Owen Mumford Ltd. (Woodstock, UK, http://www.owenmumford.com), is designed to make the administration of the drug "Kineret" easy, comfortable, and accurate in the treatment of rheumatoid arthritis (RA). When designing the SimpleJect device, Amgen worked with patients, healthcare professionals, and design experts to ensure the product would increase compliance by overcoming the often limited dexterity of RA patients, their fear of needles, and their lack of skill in administering injections. Without the SimpleJect system, many RA patients would have to rely on family members or friends every day to receive needed injections—a circumstance that would certainly cause many people to miss treatments periodically. In addition, the system automatically removes the needle cover and shields the needle from patient view during the injection process, a blessing for needle-phobic patients. A clearly written patient booklet accompanying the SimpleJect Auto-Injector system presents easy-to-understand instructions, colors, and diagrams.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here